Brought to you by 
GlaxoSmithKline acquires Sanofi-Synthelabo's antithrombotics
20 Jul 2004
Executive Summary
GlaxoSmithKline PLC has acquired the global rights to Sanofi-Synthelabo's injectable antithrombotics Arixtra (fondaparinux sodium) and Fraxiparine (nadroparine calcium) for €453mm ($547mm) in cash up front.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GlaxoSmithKline acquires Sanofi-Synthelabo's antithrombotics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice